DM Monitoring
MOSCOW: Russia plans to vaccinate more than 400,000 military personnel against COVID-19, Defence Minister Sergei Shoigu said on Friday, as authorities reported a record 27,543 new coronavirus cases.
Russia, which is working on several vaccines against the virus, has seen a surge in infections since September but authorities have resisted imposing lockdowns, relying instead on targeted measures in certain regions.
Indian pharmaceutical company Hetero will manufacture more than 100 million doses of Russia’s Sputnik V COVID-19 vaccine per year under the terms of a deal with Russia’s RDIF sovereign wealth fund unveiled on Friday. Siberia’s Vector Institute, developing EpiVacCorona, Russia’s second COVID-19 vaccine, said immunity would not be lifelong and that additional vaccinations would be required 6-10 months after the first two shots, and then once every three years.
The Vector Institute was ready to produce up to five million doses of its vaccine per year, Alexander Ryzhikov, head of the institute’s zoonotic infections and influenza department, said on Friday. Shoigu said 2,500 military personnel had been vaccinated against COVID-19 already, with the total expected to reach 80,000 by the end of the year, news agencies cited him as saying.
In Moscow, between 1,500 and 1,700 patients were being hospitalised with the virus every day, said Deputy Mayor Anastasia Rakova. “The situation with coronavirus in Moscow remains very tense, today we have recorded a so-called new anti-record,” news agencies quoted Rakova as saying, as infections in the capital surged to a record high 7,918. Despite the increase, Rakova said there were still around 5,000 hospital beds available and that 12 additional computerized tomography (CT) scan centres had been opened to provide 24-hour assistance to patients. With 2,215,533 infections, Russia has the fourth-largest number of COVID-19 cases in the world behind the United States, India and Brazil. It has recorded 38,558 deaths related to COVID-19 since the start of the pandemic.
Earlier this week, Russia said interim results from the Sputnik V clinical trials showed the vaccine was 95 percent effective, similar to other international vaccine makers that have also published test results showing efficacy rates of 90 percent and higher. Russia also announced the Sputnik V vaccine will be priced at $10 per dose on international markets, costing less than some other registered COVID-19 vaccines.
Russia was the first country to announce the registration of a coronavirus vaccine in August dubbed Sputnik V after the Soviet-era satellite but did so ahead of large scale clinical trials.
Currently, the third and final phase of trials is under way, with some 40,000 volunteers involved in blind testing of the vaccine that uses two different human adenovirus vectors.
According to Friday’s statement, their use “allows for a stronger and longer-term immune response” compared with vaccines that use the same vector in both its doses. Third phase trials are also under way in the ex-Soviet republic of Belarus, the UAE and Venezuela among other countries.
